Provasculon was founded to exploit the discovery by Richard Lee, MD, a cardiologist at Brigham and Women's Hospital and Associate Professor at Harvard Medical School, and Vincent Segers, MD, a researcher at Brigham and Women's Hospital, of novel forms of the growth factor Stromal Cell-Derived Factor-1 (SDF-1).

SDF-1 is a well characterized chemokine for attracting stem cells and represents a novel approach for tissue regeneration. A key limitation for therapeutic use of SDF-1 is that it is inactivated by enzymes that are present in injured tissues. Provasculon has licensed new forms of SDF-1 from the Brigham and Women's Hospital that in a paper published in the scientific journal Circulation have been shown to resist inactivation. These new forms represent potential therapies for cardiovascular disease and diabetic ulcers, among other indications.

Contact Information

Provasculon's facilities are located at 241 Binney Street in Cambridge, MA.

Job opportunities at Provasculon!

Press Releases